New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

KARDIGAN INC

KARD

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

11.54 0.98 −7.83%

After hours trading: 11.54, unchanged, last trade Fri 4:01pm Eastern.

Market cap
$1.2B
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
−187.2%
Net debt / EBITDA
1.7×
Payout ratio
—
Dec '25 Dec '24
Current Ratio
9.20 6.07
Net Debt/EBITDA
1.70 0.51
Debt/Equity
0.00 0.00
ROE
115.10% —
ROA
(84.47%) —
ROIC
0.00% 0.00%
Return on Tangible Assets
(61.07%) (201.32%)
Free Cash Flow per Share
(12.07) (2.05)
Book value per Share
(19.35) (8.25)
Free Cash Flow
(156.20) (20.63)
Other line items

Show all line items

Columns are period end dates · fundamentals updated Nov 18, 2026